liraglutide — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

liraglutide appears in hypotheses across 8 disease domains: ALS, Alzheimer, Depression, Epilepsy, Glioblastoma, Inflammatory bowel disease, Multiple sclerosis, Pancreatic cancer. Shared mediators that recur across at least two of those domains: AMPK, FGF21, Akt.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for liraglutide

ALS 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	amyotrophic lateral sclerosis	0.208	Mid	partial evidence	active
FGF21	tau phosphorylation	0.208	Mid	reproduces known	none

Alzheimer 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
PCSK9	Aβ accumulation	0.220	Mid	partial evidence	none

Depression 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
FGF21	depression severity	0.208	Mid	partial evidence	none
FGF21	depression trajectory	0.208	Mid	novel signal	none

Epilepsy 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
AMPK	spike-wave seizures	0.208	Mid	novel signal	none
AMPK	epileptiform network activity	0.208	Mid	novel signal	none

Glioblastoma 3

Mediator	Outcome	Score	Tier	Lit. status	Trial
Akt	subclonal progression	0.264	Mid	novel signal	none
FGF21	GBM	0.208	Mid	novel signal	none
mTOR	glioblastoma	0.208	Mid	novel signal	none

Inflammatory bowel disease 3

Mediator	Outcome	Score	Tier	Lit. status	Trial
Akt	microfilament depolymerization	0.264	Mid	novel signal	none
AMPK	intestinal epithelial repair	0.208	Mid	novel signal	none
AMPK	intestinal inflammation	0.208	Mid	partial evidence	none

Multiple sclerosis 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
FGF21	microglial amoeboid morphology	0.208	Mid	novel signal	none

Pancreatic cancer 10

Mediator	Outcome	Score	Tier	Lit. status	Trial
GLP-1R	pancreatic ductal adenocarcinoma	0.318	High	partial evidence	none
Akt	spheroid formation	0.264	Mid	novel signal	none
Akt	spheroid growth	0.264	Mid	novel signal	none
Akt	pancreatic cancer	0.264	Mid	reproduces known	completed
SIRT1	cell migration	0.220	Mid	reproduces known	none
SIRT1	proliferation	0.220	Mid	reproduces known	none
SIRT1	pancreatic cancer	0.220	Mid	reproduces known	completed
AMPK	pancreatic ductal adenocarcinoma	0.208	Mid	partial evidence	none
AMPK	pancreatic cancer progression	0.208	Mid	novel signal	none
AMPK	invasion	0.208	Mid	reproduces known	none

← All drugs